Dr. Anna Junker
Apothekerin

© dziemba














Kontakt

PharmaCampus der Westfälischen Wilhelms-Universität Münster
Institut für Pharmazeutische und Medizinische Chemie
Corrensstraße 48
48149 Münster

Tel.: +49 (0)251 83-33363
Raum: A 120.212
E-Mail

Tätigkeiten im Institut

Lehraufgaben/ Praktikumsbetreuung

  • 3. Semester: "Chemie einschließlich der Analytik der organischen Arznei-, Hilfs-, und Schadstoffe und Stereochemie"
  • beteiligt am Modul 3 (Arzneistoffchemie und Arzneibuchmethoden) des  Masterstudiengangs Arzneimittelwissenschaften
  • 5. Semester: "Arzneistoffanalytik unter besonderer Berücksichtigung der Arzneibücher (Qualitätskontrolle und Qualitätssicherung)"

Forschungsschwerpunkte

  • Synthese und Struktur-Wirkungs-Beziehungen von P2Y1 Rezeptor Antagonisten
  • Development of [11C]- and [18F]-labeled Positron Emission Tomography (PET) Tracers and Gold Nanoparticles (AuNPs) for the Selective Labeling of P2Y1 Receptor Expressing Cells – Two Different Imaging Techniques Paving the Way to Innovative Diagnostics for Prostate Cancer
  • Mitglied der Young Academy des Exzellenzclusters „Cells in Motion„ (EXC 1003 - CiM)


Publikationen
 
Dissertation
  • Synthesis of Novel Chemokine Receptor 5 Antagonists by Late-Stage Diversification and Evaluation of their Structure Affinity Relationships

Curriculum vitae

  • 11/2015 – present           Cells in Motion (Cluster of Excellence) funded Postdoctoral Fellow in the group of Prof. Dr. B. Wünsch at the Westphalian Wilhelms-University in Münster, Germany
    Development of [11C]- and [18F]-labeled Positron Emission Tomography (PET) Tracers and Gold Nanoparticles (AuNPs) for the Selective Labeling of P2Y1 Receptor Expressing Cells – Two Different Imaging Techniques Paving the Way to Innovative Diagnostics for Prostate Cancer
  • 11/2014 – 11/2015   Deutsche Forschungsgemeinschaft (DFG) funded Postdoctoral Fellow in the group of Prof. Dr. Kenneth. A. Jacobson  at the National Institutes of Health (NIH),
    Laboratory of Bioorganic Chemistry (LBC),the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), Bethesda, USA.
    Development of quantum dots (QDs) and gold nanoparticles (AuNPs) for the selective labeling of P2Y6 receptor expressing cells. 
    Structure-Based Design of Triazole Derivatives as  P2Y14 Receptor Antagonists
    Development of Potent and Selective Ecto-5’-Nucleotidase (CD73) Inhibitors
  • 09/2013 – 10/2014 Postdoctoral Fellow in the group of Prof. Dr. Christa E. Müller at the Rheinische Friedrich-Wilhelms-University in Bonn, Germany 
    Development of small molecular ligands for targeting orphan GPCRs (Neuroallianz Consortium).
  • 11/2009 – 05/2013 Ph. D. Studies at the Faculty of Pharmaceutical and Medicinal Chemistry Westphalian Wilhelms-University in Münster, Germany 
    under Supervision of Professor Dr. B. Wünsch „Synthesis of Novel Chemokine Receptor 5 Antagonists by Late-Stage Diversification and Evaluation of their Structure Affinity Relationships“
  • 01/2011 – 03/2011 and  02/2012 – 06/2012 Visiting PhD student at the Nagoya University, Japan and Group of Prof. Dr. K. Itami 
    Development of new synthetic methods for direct C-H bond functionalization of thiophene containing CCR5 ligands receptor antagonists.
  • 05/2010 – 12/2012 Member of the International Research Training Group (IRTG)
    MSNG GRK 1143: „Complex Functional Systems in Chemistry: Design, Development and Applications“
  • 01/2010 License to practice pharmacy
  • 05/2009 – 10/2009 Internship at the Westphalian Wilhelms-University, Germany
    Faculty of Pharmaceutical and Medicinal Chemistry, Group of Prof. Dr. B. Wünsch 
  • 11/2008 – 04/2009 Internship at the pharmacy „Hirsch Apotheke” in Osnabrück, Germany
  • 02/2008 – 05/2008 Internship at the „Genome Research Institute“ University of Cincinnati, USA
    Group of Professor Dr. James. J. Knittel Solid phase peptide-synthesis
  • 04/2004 – 9/2008 Study of Pharmacy  at the Westphalian Wilhelms- University in Münster, Germany


Förderungen und Preise

  • 11/2014 – 11/2015   Deutsche Forschungsgemeinschaft (DFG) funded Postdoctoral Fellow in the group of Prof. Dr. Kenneth. A. Jacobson  at the National Institutes of Health (NIH)
  • 05/2010 – 12/2012   International Research Training Group (IRTG) MSNG GRK 1143 funded doctoral fellowship

Veröffentlichungen

  • Junker, A.; Synthesis of Novel Chemokine Receptor 5 Antagonists by Late-Stage Diversification and Evaluation of their Structure Affinity Relationships. Dissertation 2013, 1-323.
  • Junker, A.; Yamaguchi, J.; Itami, K.; Wünsch, B., Synthesis of Thiophene-Based TAK779 Analogues by C–H Arylation. J. Org. Chem. 2013, 78, 5579-5586. DOI: http://pubs.acs.org/doi/abs/10.1021/jo400692p.
  • Junker, A.; Schepmann, D.; Yamaguchi, J.; Itami, K.; Faust, A.; Kopka, K.; Wagner, S.; Wünsch, B., Diverse Modification of the 4-Methylphenyl Moiety of TAK-779 by Late-Stage Suzuki-Miyaura Cross-Coupling Org. Biomol. Chem. 2014, 12, 177-186. DOI: 10.1039/C3OB41873A
  •  Junker, A.; Kokornaczyk A. K.; Strunz AK.; Wünsch, B., Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview. Topics in Medicinal Chemistry - Chemokines, Springer Berlin Heidelberg 2014, Chapter 40, 1-55. DOI: 10.1007/7355_2014_40
  • Junker, A.; Kokornaczyk, A. K.; Zweemer, A. J. M.; Frehland, B.; Schepmann, D.; Yamaguchi, J.; Itami, K.; Faust, A.; Hermann, S.; Wagner, S.; Schafers, M.; Koch, M.; Weiss, C.; Heitman, L. H.; Kopka, K.; Wunsch, B., Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Org. Biomol. Chem. 2015, 13, 2407-2422. DOI: 10.1039/C4OB02397H
  • Strunz, A. K.; Zweemer, A. J. M.; Weiss, C.; Schepmann, D.; Junker, A.; Heitman, L.; Koch, M.; Wünsch, B., Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2). Biorg. Med. Chem. 2015, 23, 4034-4049. DOI:10.1016/j.bmc.2015.02.019. 
  •  Junker, A.; Balasubramanian, R.; Ciancetta, A.; Uliassi, E.; Kiselev, E.; Martiriggiano, C.; Trujillo, K.; Mtchedlidze, G.; Birdwell, L.; Brown, K. A.; Harden, T. K.; Jacobson, K. A. Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. J. Med. Chem. 2016, 59, 6149-6168.

Posterbeiträge

  • 09/2014 DPhG Jahrestagung 2014 (Frankfurt, Germany) “Synthesis, Affinity and Structure Activity Relationships of Novel, Selective and Dual CCR2 and CCR5 Receptor Antagonists and the Development of a Selective, Fluorinated CCR2 Ligand for PET Studies”  (poster and invited talk)
  • 11/2012 IRTG-Minisymposium (Münster, Germany) “Synthesis of Novel Chemokine Receptor 5 Antagonists. Application of an Iridium-based Catalyst for the C-H Bond Activation Reaction” (poster) 
  • 04/2012 IRTG-JGGG Workshop, 3rd Anniversary of DFG office Japan (Tokyo, Japan) “Synthesis and Structure Activity Relationships of Novel Chemokine Receptor 5 Antagonists” (talk)
  • 10/2011 Joint Symposium IRTG MS-NG (Nagoya, Japan) “Synthesis and Structure Activity Relationships of Novel Chemokine Receptor 5 Antagonists” (talk)
  • 09/2011 Joint Meeting ÖPhG-DPhG (Innsbruck, Österreich) „Synthesis and Structure Activity Relationships of Novel Chemokine-Receptor 5 Antagonists” (poster)
  • 05/2011 Joint Symposium IRTG MS-NG (Münster, Germany) “Synthesis and Structure Activity Relationships of Novel Chemokine Receptor 5 Antagonists” (poster)
  • 10/2010 IRTG-Minisymposium (Münster, Germany) “Development of a [18F]-labeled PET-Tracer for the Imaging of Chemokine Receptor 5: Synthesis of the Precursors” (poster)
  • 09/2010 5th Summer School Medicinal Chemistry (Regensburg, Germany) “Synthesis of [18F]-labeled PET-Tracers for the Imaging of the Chemokine-Receptor 5” (poster, invited talk